Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Li, Pengxiang, Wong, Yu‐Ning, Armstrong, Katrina, Haas, Naomi, Subedi, Prasun, Davis‐Cerone, Margaret, Doshi, Jalpa A.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2015
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4735783/
https://ncbi.nlm.nih.gov/pubmed/26645975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.574
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares